gyki 52466 has been researched along with riluzole in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kratzer, U; Kretschmer, BD; Schmidt, WJ | 1 |
Czuczwar, SJ; Kleinrok, Z; Olszewski, K; Tutka, P; Wielosz, M; Woźniak, M | 1 |
2 other study(ies) available for gyki 52466 and riluzole
Article | Year |
---|---|
Riluzole, a glutamate release inhibitor, and motor behavior.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Catalepsy; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Locomotion; Male; Motor Activity; N-Methylaspartate; Neuropsychological Tests; Postural Balance; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Riluzole; Smell | 1998 |
Molsidomine potentiates the protective activity of GYKI 52466, a non-NMDA antagonist, MK-801, a non-competitive NMDA antagonist, and riluzole against electroconvulsions in mice.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Dizocilpine Maleate; Drug Synergism; Electroshock; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Mice; Molsidomine; Motor Activity; Nitric Oxide Synthase; Nitroarginine; Receptors, Glutamate; Riluzole | 2002 |